According to the Complaint, Carnival Corporation bills itself as the world’s largest leisure travel company and the largest cruise company, carrying nearly 45 percent of global cruise guests. The Company has operations in North America, Australia, Europe and Asia, operating a portfolio of global, regional and national cruise brands that sell tailored cruise products, services and vacation experiences on 104 cruise ships to destinations around the world.
Recent Security Class Actions
According to the Complaint, Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, and metabolic and infectious diseases. On May 8, 2020, Sorrento announced a collaboration with Mount Sinai Health System for the purpose of “generat[ing] antibody products that would act as a ‘protective shield’ against SARSCoV-2 coronavirus infection, potentially blocking and neutralizing the activity of the virus in naïve at-risk populations as well as recently infected individuals.”
According to the Complaint, Colony Capital, Inc. is a leading global investment management firm with assets under management of $55 billion. The Company manages capital on behalf of its stockholders, as well as institutional and retail investors in private funds, and traded and non-traded real estate investment trusts.
According to the Complaint, Hamilton Beach Brands Holding Co., together with its subsidiaries, designs, markets, and distributes small electric household and specialty housewares appliances. The Company sells its products through a network of mass merchandisers, e-commerce retailers, national department stores, variety and drug store chains, specialty home retailers, distributors, and other retail outlets.
According to the Complaint, Taubman Centers, Inc. is an S&P MidCap 400 Real Estate Investment Trust engaged in the ownership, management, and/or leasing of twenty-six regional, super-regional, and outlet shopping centers in the United States and Asia.
According to the Complaint, CytomX Therapeutics operates as an oncology-focused biopharmaceutical company in the U.S. The Company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. CytomX’s lead product candidates in the clinical stage include, among others, CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; and CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target.
According to the Complaint, Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.
According to the Complaint, Ryder is a global provider of transportation and supply chain management products, including leasing trucks to end users.
According to the Complaint, Elanco Animal Health Incorporated is an animal health company that develops, manufactures, and markets products for companion and food animals.
According to the Complaint, Conn’s Inc. is a specialty retailer that sells branded durable consumer goods. Conn’s has two reportable segments: (i) retail, which includes product categories such as furniture, home appliance, consumer electronics, and home office; and (ii) credit, which includes the Company’s in-house consumer credit programs.
